Evotec stock struggles after profit warning as Q2 2026 figures and guidance cuts weigh on sentiment

Evotec SE stock (ISIN DE0005664809) is trading in the low single-digit euro range in late August 2026 after a profit warning and weak second-quarter 2026 figures forced the company to slash its full-year guidance, putting sustained pressure on investor sentiment as of August 25, 2026. Per recent market data, the shares have hovered not far above their 52-week low and remain significantly below their highs from earlier in the year, underscoring how the guidance reset has reshaped expectations.

Guidance cuts and Q2 2026 weakness

An earnings and guidance overview published on August 25, 2026 shows that Evotec’s final second-quarter and first-half 2026 figures confirmed a notably weaker trajectory than initially anticipated for the year. Group revenue for the first six months of 2026 came in at EUR300.1 million, with the second quarter contributing EUR143.5 million, illustrating the scale of Evotec’s operations in the current year. The same overview highlights that these figures follow a mid-July 2026 profit warning which signaled that the year would come in well below earlier expectations.

The segment breakdown for the first half of 2026 reveals that the Discovery and Preclinical Development business generated EUR228.1 million in revenue, representing a 15.2 percent decline versus the prior-year period, while the Just-Evotec Biologics segment recorded EUR72.3 million, also down year-over-year. These declines indicate that Evotec is facing softer demand across important parts of its service portfolio at a time when it is investing in long-term projects and restructuring initiatives. The company reported an adjusted EBITDA loss of EUR42.7 million for the half-year 2026, reflecting both operational pressures and the impact of strategic programs.

The funding costs and restructuring charges associated with Evotec’s transformation plans further weighed on the 2026 interim results. Restructuring expenses tied to the Horizon program reached EUR98.9 million in the first half of 2026, while an additional impairment charge of EUR42.3 million added further pressure to the income statement. Together, these items help explain why the adjusted EBITDA has turned negative and why net income has weakened compared with 2025 levels, even as Evotec continues to position itself for longer-term growth in drug discovery and biologics manufacturing.

The effect on guidance has been pronounced. Evotec’s full-year 2026 revenue is now projected to land between EUR570 million and EUR610 million, compared with an original target range of EUR700 million to EUR780 million before the July 2026 profit warning and the subsequent Q2 figures. This represents a reduction of as much as EUR170 million at the upper end of the range and marks a clear reset of expectations for the current fiscal year. For adjusted EBITDA, the company now anticipates a loss between EUR70 million and EUR105 million for 2026, whereas it previously guided to a range between breakeven and a EUR40 million profit. The swing from a possible positive result to a planned loss underlines how much the profitability outlook has deteriorated this year.

Market reaction and valuation context

Equity market commentary dated August 24, 2026 documents that Evotec shares on Xetra were quoted at EUR3.28 at 4:28 p.m. local time, representing a decline of 2.1 percent versus the prior close and continuing the low single-digit euro range that has characterized trading in late August 2026. The same coverage notes that the shares opened that Xetra session at EUR3.33 and traded at EUR3.32 at 12:28 p.m., before sliding to EUR3.28 later in the afternoon. The progression from EUR3.33 at the open to EUR3.28 into the close reflects a modest but persistent intraday decline as investors digested the recent earnings and guidance news.

Additional reporting on August 25, 2026 indicates that the shares closed one recent trading day at EUR3.30, hovering just above a 52-week low of EUR3.19 and standing 57 percent below the year’s peak of EUR7.75, a quantified comparison that underscores the scale of the drawdown Evotec has experienced in 2026. The same analysis adds that the stock remains down about 39 percent year-to-date, showing that the selling pressure has built steadily across the year rather than being limited to a single event. For investors, these figures help frame the valuation discussion: while the price is low in absolute euro terms, it reflects a market reassessment of Evotec’s near-term earnings power.

US market data as of August 24, 2026 point to an ADR line for Evotec trading on Nasdaq under the ticker EVO. A stock overview shows the ADR quoted at $1.90 with a daily move of minus 1.81 percent at 2:22 p.m. Eastern time on that date, and provides a consensus price target of $3.00, implying 58.4 percent upside from a level of $1.89 referenced in the same dataset. The ADR-focused market data page also indicates that Evotec’s average rating score stands at 2.20 on a 0 to 4 scale, summarizing the current mix of buy, hold and sell views. These external valuations and ratings contextualize how international investors perceive the balance between Evotec’s risks and potential recovery.

The broader commentary around Evotec’s Q2 2026 results notes that analyst responses have been mixed. One detailed article from August 25, 2026 describes how one firm reaffirmed an outperform-style rating with a EUR10 price target following the publication of the final Q2 2026 numbers, while another analyst cut its third-quarter 2026 EPS estimate to a loss of $0.14 from a previously expected $0.04 deficit but maintained a buy-oriented view with a $4.00 target. The same report explains that these differing stances illustrate the uncertainty around how quickly Evotec can stabilize its margins and return to a more predictable earnings path, even as its long-term drug discovery platform remains a strategic asset.

In addition to the earnings and guidance story, late August 2026 coverage underlines that Evotec is advancing its Project Horizon transformation program, financed in part by a EUR116.1 million convertible bond issued in August 2026. One corporate-news article notes that market data in late August 2026 show Evotec shares trading in the low single-digit euro range on European exchanges, with quoted levels slightly above EUR5 on August 22, 2026 in one snapshot and lower prints nearer EUR3 in subsequent days, exemplifying how the stock has been moving in response to both funding developments and ongoing operational challenges. This corporate coverage ties the financing to Evotec’s efforts to restructure and invest in priority areas while managing near-term financial headwinds.

Profit warning, restructuring and strategy

Evotec’s mid-July 2026 profit warning was a key catalyst for the share price weakness that has persisted into late August 2026. The warning flagged that full-year 2026 results would come in materially below prior guidance, prompting the downward revision of both revenue and adjusted EBITDA targets described in the August 25, 2026 coverage. By shifting the revenue outlook to a EUR570 million to EUR610 million range from an earlier EUR700 million to EUR780 million band, Evotec signaled that demand in its core segments, including discovery services and biologics, would be weaker than initially anticipated.

The transformation program referred to as Horizon is central to Evotec’s strategy for addressing these issues. According to the same half-year 2026 analysis, restructuring costs linked to Horizon reached EUR98.9 million, and Evotec recorded a EUR42.3 million impairment, together reflecting a significant upfront investment in reshaping the portfolio and streamlining operations. While these charges have squeezed 2026 profitability and contributed to the adjusted EBITDA loss of EUR42.7 million for the half-year, management’s intention is to create a more focused platform for future growth in drug discovery collaborations and biologics production.

The combination of operational pressure and restructuring costs also plays into the company’s financing decisions. Coverage on August 24, 2026 emphasizes that a EUR116.1 million convertible bond issued in August 2026 is funding parts of Project Horizon and supporting ongoing investments in Evotec’s infrastructure and capabilities. The choice of a convertible instrument reflects a balance between raising capital and keeping flexibility in the capital structure, though it may raise dilution concerns for some shareholders if conversion occurs at current depressed share price levels.

Market commentary further notes that Evotec’s net income has weakened in Q2 2026 relative to the prior-year quarter, driven by both softer revenue and the incremental costs associated with Horizon and related initiatives. While detailed net income figures for Q2 2026 versus Q2 2025 are not fully broken out in the briefings, the narrative consistently points to a deterioration in profitability that extends beyond one-off items, suggesting that Evotec must also address underlying margin pressures in its service businesses.

Despite the near-term challenges, the earnings and guidance coverage highlights that Evotec retains a broad base of collaborations with pharmaceutical and biotechnology partners and continues to invest in platforms such as Just-Evotec Biologics. The first-half 2026 revenue of EUR300.1 million, even with the segment declines, indicates a substantial ongoing business scale. For long-term shareholders, the question is whether the Horizon program and associated investments can restore revenue growth and profitability sufficiently to justify the current guidance ranges and support a recovery from the steep share price losses recorded in 2026.

Core drug discovery platform

Evotec’s core business revolves around providing integrated drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates discovery platforms that span target identification, hit finding, lead optimization and preclinical development, and it has built capabilities in small molecules as well as biologics. The first-half 2026 revenue figures, including EUR228.1 million in Discovery and Preclinical Development and EUR72.3 million from Just-Evotec Biologics, demonstrate that these platforms remain central to Evotec’s business model even as demand fluctuations and strategic restructuring shape short-term performance.

Recent corporate coverage describing Evotec’s 2026 trajectory emphasizes that the company is aligning its operations under the Horizon program to prioritize segments with the strongest long-term potential, including biologics manufacturing and high-value discovery collaborations. This alignment is reflected in investment decisions such as the August 2026 convertible bond financing and in the willingness to incur substantial restructuring and impairment charges in the first half of 2026. The strategic focus is intended to position Evotec as a leading partner for complex drug discovery programs, leveraging its expertise and infrastructure across multiple therapeutic areas.

Evotec stock levels as of late August 2026

Evotec shares are listed on Xetra under the ticker EVT and traded in euros on their home European exchange. As of August 24, 2026, market data from the Xetra session show the stock quoted at EUR3.28 at 4:28 p.m. local time, down 2.1 percent from the previous close and continuing a pattern of trading in the low single-digit euro range in late August 2026. The intraday trading path on that date, with prints at EUR3.33 at the open, EUR3.32 around midday and EUR3.28 later in the afternoon, illustrates how the price has been reacting to ongoing earnings commentary and guidance developments in the final days of August.

In one recent closing snapshot referenced in the August 25, 2026 analysis, Evotec shares finished at EUR3.30, just above a 52-week low of EUR3.19 and far below a 2026 peak of EUR7.75, marking a decline of 57 percent from that high. The same reporting indicates that the stock is down approximately 39 percent year-to-date, quantifying the pressure that has built across the year following the mid-July profit warning and the publication of weaker Q2 2026 figures. On the US market, the Nasdaq-listed Evotec ADR under ticker EVO was last seen at $1.90 on August 24, 2026, with an analyst consensus price target of $3.00 suggesting potential upside if Evotec can stabilize its operations and deliver against its revised 2026 guidance ranges.

Read more

No additional investor relations or corporate links are included here, but investors can consult the company’s official channels and recent earnings analyses for more detail on Evotec’s 2026 guidance and strategic initiatives.

Fact box

Company: Evotec SE

ISIN: DE0005664809

Ticker: EVT

Exchange: Xetra

Sector / Industry: Health care / Biotechnology and drug discovery services